Compare Novavax Inc (NVAX) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs UiPath Inc — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while UiPath Inc trades at $12.03 (market cap $6.30B). The key difference: UiPath Inc is far larger — about 4.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | PATH | |
|---|---|---|
Market Cap | $1.30B | $6.30B |
Sector | Health | Technology |
52-Week High | $11.19 | $19.29 |
52-Week Low | $6.22 | $9.38 |
Enterprise Value | $800.50M | $5.08B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
